Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Perspectives on using a multiplex human kidney safety biomarker panel to detect cisplatin-induced tubular toxicity in male and female Cynomolgus monkeys.

Chen Y, Dale Thurman J, Kinter LB, Bialecki R, Eric McDuffie J.

Toxicol Appl Pharmacol. 2017 Dec 1;336:66-74. doi: 10.1016/j.taap.2017.10.010. Epub 2017 Oct 16.

PMID:
29051111
2.

Evaluation of Temporal Changes in Urine-based Metabolomic and Kidney Injury Markers to Detect Compound Induced Acute Kidney Tubular Toxicity in Beagle Dogs.

Wagoner MP, Yang Y, McDuffie JE, Klapczynski M, Buck W, Cheatham L, Eisinger D, Sace F, Lynch KM, Sonee M, Ma JY, Chen Y, Marshall K, Damour M, Stephen L, Dragan YP, Fikes J, Snook S, Kinter LB.

Curr Top Med Chem. 2017;17(24):2767-2780. doi: 10.2174/1568026617666170713172331.

PMID:
28714420
3.

Scientific Knowledge and Technology, Animal Experimentation, and Pharmaceutical Development.

Kinter LB, DeGeorge JJ.

ILAR J. 2016 Dec;57(2):101-108. doi: 10.1093/ilar/ilw027.

PMID:
28053064
4.

A defense of 'risk-benefit' terminology.

Kinter LB, Johnson DK.

Lab Anim (NY). 2015 Oct;44(10):403-7. doi: 10.1038/laban.875.

PMID:
26398615
5.

A Historical View and Vision into the Future of the Field of Safety Pharmacology.

Bass AS, Hombo T, Kasai C, Kinter LB, Valentin JP.

Handb Exp Pharmacol. 2015;229:3-45. doi: 10.1007/978-3-662-46943-9_1. Review.

PMID:
26091634
6.

A Standard of Knowledge for the Professional Practice of Toxicology.

Hulla JE, Kinter LB, Kelman B.

Environ Health Perspect. 2015 Aug;123(8):743-8. doi: 10.1289/ehp.1408643. Epub 2015 Mar 17.

7.

A peripherally restricted P2Y12 receptor antagonist altered rat tumor incidences with no human relevance: Mode of action consistent with dopamine agonism.

Brott DA, Andersson HAS, Stewart J, Ewart L, Christoph G, Harleman J, Armstrong D, Kinter LB.

Toxicol Rep. 2014 Nov 20;1:1202-1212. doi: 10.1016/j.toxrep.2014.11.010. eCollection 2014.

8.

Pharmaceutical toxicology: designing studies to reduce animal use, while maximizing human translation.

Chapman KL, Holzgrefe H, Black LE, Brown M, Chellman G, Copeman C, Couch J, Creton S, Gehen S, Hoberman A, Kinter LB, Madden S, Mattis C, Stemple HA, Wilson S.

Regul Toxicol Pharmacol. 2013 Jun;66(1):88-103. doi: 10.1016/j.yrtph.2013.03.001. Epub 2013 Mar 21.

9.

Renal biomarker changes associated with hyaline droplet nephropathy in rats are time and potentially compound dependent.

Brott DA, Bentley P, Nadella MV, Thurman D, Fikes J, Cheatham L, McGrath F, Luo W, Kinter LB.

Toxicology. 2013 Jan 7;303:133-8. doi: 10.1016/j.tox.2012.11.003. Epub 2012 Nov 14.

PMID:
23159986
10.

Inhibition of oestradiol-induced prolactin release in a dual-cannulated ovariectomized rat model by carmoxirole, a peripherally restricted dopamine agonist.

Brott DA, Werkheiser JL, Campbell P, Bentley P, Andersson HH, Stewart J, Huby R, Altekar M, Kinter LB.

Basic Clin Pharmacol Toxicol. 2012 Dec;111(6):411-6. doi: 10.1111/j.1742-7843.2012.00918.x. Epub 2012 Jul 31.

11.

Safety pharmacology in 2010 and beyond: survey of significant events of the past 10 years and a roadmap to the immediate-, intermediate- and long-term future in recognition of the tenth anniversary of the Safety Pharmacology Society.

Bass AS, Vargas HM, Valentin JP, Kinter LB, Hammond T, Wallis R, Siegl PK, Yamamoto K.

J Pharmacol Toxicol Methods. 2011 Jul-Aug;64(1):7-15. doi: 10.1016/j.vascn.2011.05.006. Epub 2011 Jun 12. Review.

PMID:
21689769
12.

In vivo and in vitro liver and gill EROD activity in rainbow trout (Oncorhynchus mykiss) exposed to the beta-blocker propranolol.

Bartram AE, Winter MJ, Huggett DB, McCormack P, Constantine LA, Hetheridge MJ, Hutchinson TH, Kinter LB, Ericson JF, Sumpter JP, Owen SF.

Environ Toxicol. 2012 Oct;27(10):573-82. doi: 10.1002/tox.20684. Epub 2011 Mar 7.

PMID:
21384489
13.

Conference Report: DIA/PhRMA workshop on DBS sampling in the pharmaceutical industry: methodology, implementation & best practices.

Evans CA, Bruce C, Emmons GT, Gallenberg L, Ji QC, Kinter LB, Musvasva E, Wickremsinhe E.

Bioanalysis. 2010 Aug;2(8):1355-9. doi: 10.4155/bio.10.101. No abstract available.

14.

The value of repeating studies and multiple controls: replicated 28-day growth studies of rainbow trout exposed to clofibric acid.

Owen SF, Huggett DB, Hutchinson TH, Hetheridge MJ, McCormack P, Kinter LB, Ericson JF, Constantine LA, Sumpter JP.

Environ Toxicol Chem. 2010 Dec;29(12):2831-9. doi: 10.1002/etc.351. Epub 2010 Oct 23.

PMID:
20836071
15.

Using data from drug discovery and development to aid the aquatic environmental risk assessment of human pharmaceuticals: concepts, considerations, and challenges.

Winter MJ, Owen SF, Murray-Smith R, Panter GH, Hetheridge MJ, Kinter LB.

Integr Environ Assess Manag. 2010 Jan;6(1):38-51. doi: 10.1897/IEAM_2009-044.1. Review.

PMID:
19558206
16.

Uptake of propranolol, a cardiovascular pharmaceutical, from water into fish plasma and its effects on growth and organ biometry.

Owen SF, Huggett DB, Hutchinson TH, Hetheridge MJ, Kinter LB, Ericson JF, Sumpter JP.

Aquat Toxicol. 2009 Jul 26;93(4):217-24. doi: 10.1016/j.aquatox.2009.05.009. Epub 2009 May 15.

PMID:
19515433
17.

Drugs effects on ventricular repolarization: a critical evaluation of the strengths and weaknesses of current methodologies and regulatory practices.

Bass AS, Tomaselli G, Bullingham R 3rd, Kinter LB.

J Pharmacol Toxicol Methods. 2005 Jul-Aug;52(1):12-21. Review.

PMID:
15967683
18.

New preclinical guidelines on drug effects on ventricular repolarization: safety pharmacology comes of age.

Kinter LB, Siegl PK, Bass AS.

J Pharmacol Toxicol Methods. 2004 May-Jun;49(3):153-8. Review. No abstract available.

PMID:
15172011
19.

Introduction to nonclinical safety pharmacology and the safety pharmacology society.

Bass AS, Vargas HM, Kinter LB.

J Pharmacol Toxicol Methods. 2004 May-Jun;49(3):141-4. No abstract available.

PMID:
15172009
20.

Evaluation and applications of radiotelemetry in small laboratory animals.

Kramer K, Kinter LB.

Physiol Genomics. 2003 May 13;13(3):197-205. Epub 2003 May 13. Review.

PMID:
12746464
21.

Safety pharmacology and risk assessment.

Kinter LB, Valentin JP.

Fundam Clin Pharmacol. 2002 Jun;16(3):175-82. Review.

PMID:
12165065
22.

Polymeric gadolinium chelate magnetic resonance imaging contrast agents: design, synthesis, and properties.

Ladd DL, Hollister R, Peng X, Wei D, Wu G, Delecki D, Snow RA, Toner JL, Kellar K, Eck J, Desai VC, Raymond G, Kinter LB, Desser TS, Rubin DL.

Bioconjug Chem. 1999 May-Jun;10(3):361-70.

PMID:
10346865
23.

Etiologic significance of arginine vasopressin in motion sickness.

Cheung BS, Kohl RL, Money KE, Kinter LB.

J Clin Pharmacol. 1994 Jun;34(6):664-70.

PMID:
8083398
24.

The application of toxicokinetic data to dosage selection in toxicology studies.

Morgan DG, Kelvin AS, Kinter LB, Fish CJ, Kerns WD, Rhodes G.

Toxicol Pathol. 1994 Mar-Apr;22(2):112-23.

PMID:
7973359
25.

Effects of catechol ring fluorination on cardiovascular and renal activities of fenoldopam enantiomers.

Kinter LB, Mann WA, Weinstock J, Ruffolo RR Jr.

Chirality. 1994;6(5):446-55.

PMID:
7915128
26.

Urea transport in toad skin (Bufo marinus)

Dytko G, Smith PL, Kinter LB.

J Pharmacol Exp Ther. 1993 Oct;267(1):364-70. Erratum in: J Pharmacol Exp Ther 1994 Apr;269(1):449.

PMID:
8229763
27.

Antagonism of antidiuretic hormone in domestic pigs (Sus scrofa).

Monaghan ML, Divers T, Huffman WF, Kinter LB.

Gen Pharmacol. 1993 Jul;24(4):1013-20.

PMID:
8224729
28.

Anomalous antidiuretic activity of antidiuretic hormone antagonists.

Kinter LB, Caltabiano S, Huffman WF.

Biochem Pharmacol. 1993 May 5;45(9):1731-7. Review. No abstract available.

PMID:
8494530
29.
30.

Characterization of maximal intravenous dose volumes in the dog (Canis familiaris).

Mann WA, Kinter LB.

Gen Pharmacol. 1993 Mar;24(2):357-66.

PMID:
8482520
31.

Vasopressin antagonist inhibition of clotting factor release in the rhesus monkey (Macaca mulatta).

Kinter LB, McConnell I, Goodwin BT, Campbell S, Huffman WF, Arthus MF, Lonergan M, Bichet DG.

J Pharmacol Exp Ther. 1992 May;261(2):462-9.

PMID:
1578361
32.

Investigation of anti-motion sickness drugs in the squirrel monkey.

Cheung BS, Money KE, Kohl RL, Kinter LB.

J Clin Pharmacol. 1992 Feb;32(2):163-75.

PMID:
1613127
33.

Characterization of the renal effects and renal elimination of sulotroban in the dog.

Mann WA, Welzel GE, Goldstein RS, Sozio RS, Cyronak MJ, Kao J, Kinter LB.

J Pharmacol Exp Ther. 1991 Dec;259(3):1231-40.

PMID:
1762070
34.
35.

Effect of V1/V2-receptor antagonism on renal function and response to vasopressin in conscious dogs.

Rose CE Jr, Rose KY, Kinter LB.

Am J Physiol. 1991 Feb;260(2 Pt 2):F273-82.

PMID:
1825453
36.

Yb-DTPA, a novel contrast agent in magnetic resonance imaging: application to rat kidney.

Sarkar SK, Rycyna RE, Lenkinski RE, Solleveld HA, Kinter LB.

Magn Reson Med. 1991 Feb;17(2):328-35.

PMID:
2062207
37.

Vasopressin antidiuretic agonist and antagonist activity in dogs: structural and stereochemical relationship between bridge and carboxyl terminus.

Albrightson-Winslow CR, Brickson B, Brooks DP, Bryan WM, Caldwell N, Kinter LB, Moore ML, Nambi P, Stassen FL, Huffman WF.

J Pharmacol Exp Ther. 1991 Jan;256(1):335-40.

PMID:
1988664
38.

Effect of cyclo-oxygenase blockade on the renal actions of vasopressin and SK&F 105494 in the rhesus monkey.

Brooks DP, Caldwell NC, Koster PF, Albrightson-Winslow CR, Kinter LB.

Br J Pharmacol. 1990 Apr;99(4):750-2.

39.

Physiological regulation of the renal vasopressin receptor-effector pathway in dogs.

Kinter LB, Caldwell N, Caltabiano S, Winslow C, Brooks DP, Huffman WF.

Am J Physiol. 1990 Mar;258(3 Pt 2):R763-9.

PMID:
2138428
40.

Characterization of the hemodynamic activities of fenoldopam and its enantiomers in the dog.

Kinter LB, Horner E, Mann WA, Weinstock J, Ruffolo RR Jr.

Chirality. 1990;2(4):219-25.

PMID:
1982058
41.

Production of methylguanidine in dogs with acute and chronic renal failure.

Brooks DP, Rhodes GR, Woodward P, Boppana VK, Mallon FM, Griffin HE, Kinter LB.

Clin Sci (Lond). 1989 Dec;77(6):637-41.

PMID:
2605868
42.

Noncyclic vasopressin analogs are effective diuretics in conscious rats.

Uyehara CF, Caltabiano S, Kinter LB, Gellai M.

J Pharmacol Exp Ther. 1989 Dec;251(3):1128-33.

PMID:
2600807
43.

Effect of a selective V1 vasopressin receptor antagonist on the sequelae of endotoxemia in the conscious rat.

Egan JW, Jugus M, Kinter LB, Lee K, Smith EF 3rd.

Circ Shock. 1989 Oct;29(2):155-66.

PMID:
2684446
44.

Cyclooxygenase inhibition unmasks the full antidiuretic agonist activity of the vasopressin antagonist, SK&F 101926, in dogs.

Albrightson-Winslow CR, Caldwell N, Brooks DP, Huffman WF, Stassen FL, Kinter LB.

J Pharmacol Exp Ther. 1989 May;249(2):366-71.

PMID:
2524585
45.

A minor modification of residue 1 in potent vasopressin antagonists dramatically reduces agonist activity.

Huffman WF, Albrightson-Winslow C, Brickson B, Bryan HG, Caldwell N, Dytko G, Eggleston DS, Kinter LB, Moore ML, Newlander KA, et al.

J Med Chem. 1989 Apr;32(4):880-4.

PMID:
2522994
46.

Renal microvascular effects of vasopressin and vasopressin antagonists.

Edwards RM, Trizna W, Kinter LB.

Am J Physiol. 1989 Feb;256(2 Pt 2):F274-8.

PMID:
2916660
47.

Structure-activity relationships of novel vasopressin antagonists containing C-terminal diaminoalkanes and (aminoalkyl)guanidines.

Callahan JF, Ashton-Shue D, Bryan HG, Bryan WM, Heckman GD, Kinter LB, McDonald JE, Moore ML, Schmidt DB, Silvestri JS, et al.

J Med Chem. 1989 Feb;32(2):391-6.

PMID:
2521519
48.

Vasopressin receptor antagonism in rhesus monkey and man: stereochemical requirements.

Brooks DP, Koster PF, Albrightson CR, Huffman WF, Moore ML, Stassen FL, Schmidt DB, Kinter LB.

Eur J Pharmacol. 1989 Jan 24;160(1):159-62.

PMID:
2540987
50.

SK&F 105494: a potent antidiuretic hormone antagonist devoid of partial agonist activity in dogs.

Caldwell N, Brickson B, Kinter LB, Brooks DP, Huffman WF, Stassen FL, Albrightson-Winslow C.

J Pharmacol Exp Ther. 1988 Dec;247(3):897-901.

PMID:
3204522

Supplemental Content

Loading ...
Support Center